{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T09:49:32Z","timestamp":1662198572681},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1007\/s00115-005-1888-7","type":"journal-article","created":{"date-parts":[[2005,3,17]],"date-time":"2005-03-17T06:36:45Z","timestamp":1111041405000},"page":"1062-1076","source":"Crossref","is-referenced-by-count":7,"title":["Das endogene Cannabinoidsystem"],"prefix":"10.1007","volume":"76","author":[{"given":"U.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Karst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Schlimme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Cimander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. R.","family":"M\u00fcller-Vahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1888_CR1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0301-0082(98)00087-2","volume":"58","author":"Ameri","year":"1999","unstructured":"Ameri A (1999) The effects of cannabinoids on the brain. Prog Neurobiol 58:315\u2013348","journal-title":"Prog Neurobiol"},{"key":"1888_CR2","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/sj.bjp.0702478","volume":"126","author":"Ameri","year":"1999","unstructured":"Ameri A, Wilhelm A, Simmet T (1999) Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices. Br J Pharmacol 126:1831\u20131839","journal-title":"Br J Pharmacol"},{"key":"1888_CR3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/35003583","volume":"404","author":"Baker","year":"2000","unstructured":"Baker D, Pryce G, Croxford JL et al. (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404:84\u201387","journal-title":"Nature"},{"key":"1888_CR4","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1096\/fj.00-0399fje","volume":"15","author":"Baker","year":"2001","unstructured":"Baker D, Pryce G, Croxford JL et al. (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15:300\u2013302","journal-title":"FASEB J"},{"key":"1888_CR5","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.biopsych.2004.01.005","volume":"55","author":"Berding","year":"2004","unstructured":"Berding G, Muller-Vahl K, Schneider U et al. (2004) [(123)I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB(1) receptors before and after Delta(9)-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. Biol Psychiatry 55:904\u2013915","journal-title":"Biol Psychiatry"},{"key":"1888_CR6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/mol.60.1.155","volume":"60","author":"Breivogel","year":"2001","unstructured":"Breivogel CS, Griffin G, Di Marzo V et al. (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60:155\u2013163","journal-title":"Mol Pharmacol"},{"key":"1888_CR7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000227126","volume":"49","author":"Bruera","year":"1992","unstructured":"Bruera E (1992) Clinical mangement of anorexia and chachexia in patients with advanced cancer. Oncology 49:35\u201342","journal-title":"Oncology"},{"key":"1888_CR8","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2174\/1381612003399473","volume":"6","author":"Burstein","year":"2000","unstructured":"Burstein SH (2000) Ajulemic acid (CT3): a potent analog of the acid metabolites of THC. Curr Pharm Des 6:1339\u20131345","journal-title":"Curr Pharm Des"},{"key":"1888_CR9","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.lfs.2004.04.010","volume":"75","author":"Burstein","year":"2004","unstructured":"Burstein SH, Karst M, Schneider U et al. (2004) Ajulemic acid: a novel cannabinoid produces analgesia without a \u201ehigh\u201c. Life Sci 75:1513\u20131522","journal-title":"Life Sci"},{"key":"1888_CR10","unstructured":"Bundeszentrale f\u00fcr gesundheitliche Aufkl\u00e4rung (BzgA) (2001) Die Drogenaffinit\u00e4t Jugendlicher in der Bundesrepublik Deutschland. BzgA, K\u00f6ln"},{"key":"1888_CR11","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/0024-3205(95)00190-H","volume":"56","author":"Cabral","year":"1995","unstructured":"Cabral GA, Toney DM, Fischer-Stenger K et al. (1995) Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. Life Sci 56:2065\u20132072","journal-title":"Life Sci"},{"key":"1888_CR12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4684-5925-8_10","volume":"288","author":"Cabral","year":"1991","unstructured":"Cabral GA, Vasquez R (1991) Effects of marijuana on macrophage function. Adv Exp Med Biol 288:93\u2013105","journal-title":"Adv Exp Med Biol"},{"key":"1888_CR13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/bmj.323.7303.13","volume":"323","author":"Campbell","year":"2001","unstructured":"Campbell FA, Tramer MR, Carroll D et al. (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 323:13\u201316","journal-title":"BMJ"},{"key":"1888_CR14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1469-7793.1999.00539.x","volume":"520","author":"Chaytor","year":"1999","unstructured":"Chaytor A, Martin P, Evans W et al. (1999) The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol 520(Pt 2):539\u2013550","journal-title":"J Physiol"},{"key":"1888_CR15","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.bjp.0703930","volume":"132","author":"Christopoulos","year":"2001","unstructured":"Christopoulos A, Coles P, Lay L et al. (2001) Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens. Br J Pharmacol 132:1281\u20131291","journal-title":"Br J Pharmacol"},{"key":"1888_CR16","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/ana.410130616","volume":"13","author":"Clifford","year":"1983","unstructured":"Clifford DB (1983) Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 13:669\u2013671","journal-title":"Ann Neurol"},{"key":"1888_CR17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0014-2999(82)90264-3","volume":"83","author":"Consroe","year":"1982","unstructured":"Consroe P, Benedito MA, Leite JR et al. (1982) Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 83:293\u2013298","journal-title":"Eur J Pharmacol"},{"key":"1888_CR18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","volume":"40","author":"Consroe","year":"1991","unstructured":"Consroe P, Laguna J, Allender J et al. (1991) Controlled clinical trial of cannabidiol in Huntington\u2019s disease. Pharmacol Biochem Behav 40:701\u2013708","journal-title":"Pharmacol Biochem Behav"},{"key":"1888_CR19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/00207458608985678","volume":"30","author":"Consroe","year":"1986","unstructured":"Consroe P, Sandyk R, Snider SR (1986) Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 30:277\u2013282","journal-title":"Int J Neurosci"},{"key":"1888_CR20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.ijo.0802250","volume":"27","author":"Cota","year":"2003","unstructured":"Cota D, Marsicano G, Lutz B et al. (2003) Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 27:289\u2013301","journal-title":"Int J Obes Relat Metab Disord"},{"key":"1888_CR21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000137430","volume":"21","author":"Cunha","year":"1980","unstructured":"Cunha JM, Carlini EA, Pereira AE et al. (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21:175\u2013185","journal-title":"Pharmacology"},{"key":"1888_CR22","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0959-4388(02)00340-9","volume":"12","author":"Di","year":"2002","unstructured":"Di Marzo V, Blumberg PM, Szallasi A (2002) Endovanilloid signaling in pain. Curr Opin Neurobiol 12:372\u2013379","journal-title":"Curr Opin Neurobiol"},{"key":"1888_CR23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0166-2236(98)01283-1","volume":"21","author":"Di","year":"1998","unstructured":"Di Marzo V, Melck D, Bisogno T et al. (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci 21:521\u2013528","journal-title":"Trends Neurosci"},{"key":"1888_CR24","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1517\/13543784.10.10.1831","volume":"10","author":"Diener","year":"2001","unstructured":"Diener HC, Limmroth V (2001) Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 10:1831\u20131845","journal-title":"Expert Opin Investig Drugs"},{"key":"1888_CR25","first-page":"10","volume":"146","author":"Einecke","year":"2004","unstructured":"Einecke D (2004) [A new pill for metabolic syndrome. Successful control of lipids, kilos and cigarettes]. MMW Fortschr Med 146:10\u201311","journal-title":"MMW Fortschr Med"},{"key":"1888_CR26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/jat\/25.7.565","volume":"25","author":"Elsohly","year":"2001","unstructured":"Elsohly MA, Dewit H, Wachtel SR et al. (2001) Delta9-tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol: results of a clinical study. J Anal Toxicol 25:565\u2013571","journal-title":"J Anal Toxicol"},{"key":"1888_CR27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0166-2236(99)01491-5","volume":"23","author":"Fernandez-Ruiz","year":"2000","unstructured":"Fernandez-Ruiz J, Berrendero F, Hernandez ML et al. (2000) The endogenous cannabinoid system and brain development. Trends Neurosci 23:14\u201320","journal-title":"Trends Neurosci"},{"key":"1888_CR28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/mds.1280","volume":"17","author":"Fox","year":"2002","unstructured":"Fox SH, Kellett M, Moore AP et al. (2002) Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 17:145\u2013149","journal-title":"Mov Disord"},{"key":"1888_CR29","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/jnnp.53.5.436","volume":"53","author":"Frankel","year":"1990","unstructured":"Frankel JP, Hughes A, Lees AJ et al. (1990) Marijuana for parkinsonian tremor. J Neurol Neurosurg Psychiatry 53:436","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1888_CR30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1054\/plef.2001.0360","volume":"66","author":"Fride","year":"2002","unstructured":"Fride E (2002) Endocannabinoids in the central nervous system\u2014an overview. Prostaglandins Leukot Essent Fatty Acids 66:221\u2013233","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"1888_CR31","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1111\/j.0953-816X.2004.03384.x","volume":"19","author":"Fukudome","year":"2004","unstructured":"Fukudome Y, Ohno-Shosaku T, Matsui M et al. (2004) Two distinct classes of muscarinic action on hippocampal inhibitory synapses: M2-mediated direct suppression and M1\/M3-mediated indirect suppression through endocannabinoid signalling. Eur J Neurosci 19:2682\u20132692","journal-title":"Eur J Neurosci"},{"key":"1888_CR32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","volume":"232","author":"Galiegue","year":"1995","unstructured":"Galiegue S, Mary S, Marchand J et al. (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54\u201361","journal-title":"Eur J Biochem"},{"key":"1888_CR33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0009-3084(00)00193-6","volume":"108","author":"Giuffrida","year":"2000","unstructured":"Giuffrida A, Piomelli D (2000) The endocannabinoid system: a physiological perspective on its role in psychomotor control. Chem Phys Lipids 108:151\u2013158","journal-title":"Chem Phys Lipids"},{"key":"1888_CR34","first-page":"14","volume":"25","author":"Grotenhermen","year":"2004","unstructured":"Grotenhermen F (2004) Pharmacology of cannabinoids. Neuroendocrinol Lett 25:14\u201323","journal-title":"Neuroendocrinol Lett"},{"key":"1888_CR35","unstructured":"Grotenhermen F (2004) Hanf als Medizin. AT Verlag, Baden"},{"key":"1888_CR36","doi-asserted-by":"crossref","unstructured":"Guimaraes F, Chiaretti T, Graeff F et al. (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) 100:558\u2013559","DOI":"10.1007\/BF02244012"},{"key":"1888_CR37","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/S0024-3205(01)01539-9","volume":"70","author":"Habayeb","year":"2002","unstructured":"Habayeb OM, Bell SC, Konje JC (2002) Endogenous cannabinoids: metabolism and their role in reproduction. Life Sci 70:1963\u20131977","journal-title":"Life Sci"},{"key":"1888_CR38","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.fbp.0000135704.56422.40","volume":"15","author":"Haller","year":"2004","unstructured":"Haller J, Varga B, Ledent C et al. (2004) CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 15:299\u2013304","journal-title":"Behav Pharmacol"},{"key":"1888_CR39","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.1073\/pnas.95.14.8268","volume":"95","author":"Hampson","year":"1998","unstructured":"Hampson A, Grimaldi M, Axelrod J et al. (1998) Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95:8268\u20138273","journal-title":"Proc Natl Acad Sci USA"},{"key":"1888_CR40","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1073\/pnas.061029898","volume":"98","author":"Hanus","year":"2001","unstructured":"Hanus L, Abu-Lafi S, Fride E et al. (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98:3662\u20133665","journal-title":"Proc Natl Acad Sci USA"},{"key":"1888_CR41","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1002\/mds.20214","volume":"19","author":"Jabusch","year":"2004","unstructured":"Jabusch JC, Schneider U, Altenmueller E (2004) Delta-9-Tetrahydrocannabinol (THC) in treatment of muscian\u2019s dystonia. Mov Disord 19:990\u2013991","journal-title":"Mov Disord"},{"key":"1888_CR42","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1192\/bjp.178.2.116","volume":"178","author":"Johns","year":"2001","unstructured":"Johns A (2001) Psychiatric effects of cannabis. Br J Psychiatry 178:116\u2013122","journal-title":"Br J Psychiatry"},{"key":"1888_CR43","first-page":"103","volume":"120","author":"Karst","year":"2003","unstructured":"Karst M, Salim K, Conrad I et al. (2003) Analgesic effects of synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 120:103\u2013105","journal-title":"JAMA"},{"key":"1888_CR44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nm803","volume":"9","author":"Kathuria","year":"2003","unstructured":"Kathuria S, Gaetani S, Fegley D et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76\u201381","journal-title":"Nat Med"},{"key":"1888_CR45","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1212\/WNL.58.9.1404","volume":"58","author":"Killestein","year":"2002","unstructured":"Killestein J, Hoogervorst EL, Reif M et al. (2002) Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 58:1404\u20131407","journal-title":"Neurology"},{"key":"1888_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1525-1373.2000.22501.x","volume":"225","author":"Klein","year":"2000","unstructured":"Klein TW, Lane B, Newton CA et al. (2000) The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 225:1\u20138","journal-title":"Proc Soc Exp Biol Med"},{"key":"1888_CR47","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00003246-200203000-00009","volume":"30","author":"Knoller","year":"2002","unstructured":"Knoller N, Levi L, Shoshan I et al. (2002) Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial. Crit Care Med 30:548\u2013554","journal-title":"Crit Care Med"},{"key":"1888_CR48","unstructured":"Kraus L, Augustin R, M\u00fcller-Klathoff T (2001) Konsumtrends und Konsumverhalten. H\u00fcllinghorst RNeuland, Geesthacht, S\u00a0119\u2013132"},{"key":"1888_CR49","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0896-6273(01)00246-X","volume":"29","author":"Kreitzer","year":"2001","unstructured":"Kreitzer AC, Regehr WG (2001) Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29:717\u2013727","journal-title":"Neuron"},{"key":"1888_CR50","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2174\/0929867023370707","volume":"9","author":"Lambert","year":"2002","unstructured":"Lambert D, Vandevoorde S, Jonsson K et al. (2002) The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem 9:663\u2013674","journal-title":"Curr Med Chem"},{"key":"1888_CR51","first-page":"498","volume":"7","author":"Lange","year":"2004","unstructured":"Lange J, Kruse C (2004) Recent advances in CB1 cannabinoid receptor antagonists. Curr Opin Drug Discov Devel 7:498\u2013506","journal-title":"Curr Opin Drug Discov Devel"},{"key":"1888_CR52","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1161\/01.STR.0000079817.68944.1E","volume":"34","author":"Leker","year":"2003","unstructured":"Leker R, Gai N, Mechoulam R et al. (2003) Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke 34:2000\u20132006","journal-title":"Stroke"},{"key":"1888_CR53","doi-asserted-by":"crossref","unstructured":"Lichtman AH, Dimen KR, Martin BR (1995) Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl) 119:282\u2013290","DOI":"10.1007\/BF02246292"},{"key":"1888_CR54","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1124\/mol.63.5.983","volume":"63","author":"Liu","year":"2003","unstructured":"Liu J, Li H, Burstein SH et al. (2003) Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol Pharmacol 63:983\u2013992","journal-title":"Mol Pharmacol"},{"key":"1888_CR55","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/jlb.39.6.679","volume":"39","author":"Lopez-Cepero","year":"1986","unstructured":"Lopez-Cepero M, Friedman M, Klein T et al. (1986) Tetrahydrocannabinol-induced suppression of macrophage spreading and phagocytic activity in vitro. J Leukoc Biol 39:679\u2013686","journal-title":"J Leukoc Biol"},{"key":"1888_CR56","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0165-5728(89)90075-1","volume":"23","author":"Lyman","year":"1989","unstructured":"Lyman WD, Sonett JR, Brosnan CF et al. (1989) Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 23:73\u201381","journal-title":"J Neuroimmunol"},{"key":"1888_CR57","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1046\/j.1471-4159.2001.00092.x","volume":"76","author":"Maccarrone","year":"2001","unstructured":"Maccarrone M, Attina M, Cartoni A et al. (2001) Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture. J Neurochem 76:594\u2013601","journal-title":"J Neurochem"},{"key":"1888_CR58","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0083-6729(02)65066-6","volume":"65","author":"Maccarrone","year":"2002","unstructured":"Maccarrone M, Finazzi-Agro A (2002) Endocannabinoids and their actions. Vitam Horm 65:225\u2013255","journal-title":"Vitam Horm"},{"key":"1888_CR59","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI200419465","volume":"113","author":"Massa","year":"2004","unstructured":"Massa F, Marsicano G, Hermann H et al. (2004) The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113:1202\u20131209","journal-title":"J Clin Invest"},{"key":"1888_CR60","first-page":"618","volume":"291","author":"Mcallister","year":"1999","unstructured":"Mcallister S, Griffin G, Satin L et al. (1999) Cannabinoid receptors can activate and inhibit G protein-coupled inwardly rectifying potassium channels in a xenopus oocyte expression system. J Pharmacol Exp Ther 291:618\u2013626","journal-title":"J Pharmacol Exp Ther"},{"key":"1888_CR61","first-page":"1620","volume":"289","author":"Mccoy","year":"1999","unstructured":"Mccoy KL, Matveyeva M, Carlisle SJ et al. (1999) Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J Pharmacol Exp Ther 289:1620\u20131625","journal-title":"J Pharmacol Exp Ther"},{"key":"1888_CR62","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1471-4914(02)02276-1","volume":"8","author":"Mechoulam","year":"2002","unstructured":"Mechoulam R, Panikashvili D, Shohami E (2002) Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 8:58\u201361","journal-title":"Trends Mol Med"},{"key":"1888_CR63","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3940(02)00936-9","volume":"332","author":"Milton","year":"2002","unstructured":"Milton NG (2002) Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide. Neurosci Lett 332:127\u2013130","journal-title":"Neurosci Lett"},{"key":"1888_CR64","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s00210-004-0921-x","volume":"369","author":"Moranta","year":"2004","unstructured":"Moranta D, Esteban S, Garcia-Sevilla JA (2004) Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 369:516\u2013524","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1888_CR65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-2001-15191","volume":"34","author":"Mueller-Vahl","year":"2001","unstructured":"Mueller-Vahl KR, Koblenz A, Jobges M et al. (2001) Influence of treatment of Tourette syndrome with delta9-tetrahydrocannabinol (delta9-THC) on neuropsychological performance. Pharmacopsychiatry 34:19\u201324","journal-title":"Pharmacopsychiatry"},{"key":"1888_CR66","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/1531-8257(199911)14:6<1038::AID-MDS1024>3.0.CO;2-7","volume":"14","author":"Mueller-Vahl","year":"1999","unstructured":"Mueller-Vahl KR, Schneider U, Emrich HM (1999) Nabilone increases choreatic movements in Huntington\u2019s disease. Mov Disord 14:1038\u20131040","journal-title":"Mov Disord"},{"key":"1888_CR67","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-2002-25028","volume":"35","author":"Mueller-Vahl","year":"2002","unstructured":"Mueller-Vahl KR, Schneider U, Koblenz A et al. (2002) Treatment of Tourette\u2019s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35:57\u201361","journal-title":"Pharmacopsychiatry"},{"key":"1888_CR68","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/sj.npp.1300047","volume":"28","author":"Mueller-Vahl","year":"2003","unstructured":"Mueller-Vahl KR, Prevedel H, Theloe K et al. (2003) Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology 28:384\u2013388","journal-title":"Neuropsychopharmacology"},{"key":"1888_CR69","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4088\/JCP.v64n0417","volume":"64","author":"Mueller-Vahl","year":"2003","unstructured":"Mueller-Vahl KR, Schneider U, Prevedel H et al. (2003) Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 64:459\u2013465","journal-title":"J Clin Psychiatry"},{"key":"1888_CR70","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0304-3959(03)00163-5","volume":"105","author":"Naef","year":"2003","unstructured":"Naef M, Curatolo M, Petersen-Felix S et al. (2003) The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 105:79\u201388","journal-title":"Pain"},{"key":"1888_CR71","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1007\/s00115-004-1738-z","volume":"75","author":"Neuhaus","year":"2004","unstructured":"Neuhaus O, Kieseier B, Klimke A et al. (2004) Cannabinoids in multiple sclerosis Opportunity or threat?. Nervenarzt 75:1022\u20131026","journal-title":"Nervenarzt"},{"key":"1888_CR72","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0896-6273(01)00247-1","volume":"29","author":"Ohno-Shosaku","year":"2001","unstructured":"Ohno-Shosaku T, Maejima T, Kano M (2001) Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 29:729\u2013738","journal-title":"Neuron"},{"key":"1888_CR73","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1054\/plef.2001.0355","volume":"66","author":"Parolaro","year":"2002","unstructured":"Parolaro D, Massi P, Rubino T et al. (2002) Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids 66:319\u2013332","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"1888_CR74","first-page":"129","volume":"74","author":"Pertwee","year":"1997","unstructured":"Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129\u2013180","journal-title":"Pharmacol Ther"},{"key":"1888_CR75","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0301-0082(00)00031-9","volume":"63","author":"Pertwee","year":"2001","unstructured":"Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569\u2013611","journal-title":"Prog Neurobiol"},{"key":"1888_CR76","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/j.1552-4604.1981.tb02621.x","volume":"21","author":"Petro","year":"1981","unstructured":"Petro DJ, Ellenberger CJ (1981) Treatment of human spasticity with delta 9-tetrahydrocannabinol. J Clin Pharmacol 21:413\u2013416","journal-title":"J Clin Pharmacol"},{"key":"1888_CR77","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1124\/jpet.301.3.1020","volume":"301","author":"Porter","year":"2002","unstructured":"Porter A, Sauer J, Knierman M et al. (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301:1020\u20131024","journal-title":"J Pharmacol Exp Ther"},{"key":"1888_CR78","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1016\/S0024-3205(02)02086-6","volume":"71","author":"Ralevic","year":"2002","unstructured":"Ralevic V, Kendall DA, Randall MD et al. (2002) Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function. Life Sci 71:2577\u20132594","journal-title":"Life Sci"},{"key":"1888_CR79","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1054\/plef.2001.0362","volume":"66","author":"Rice","year":"2002","unstructured":"Rice AS, Farquhar-Smith WP, Nagy I (2002) Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 66:243\u2013256","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"1888_CR80","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0304-3959(98)00033-5","volume":"76","author":"Russo","year":"1998","unstructured":"Russo E (1998) Cannabis for migraine treatment: the once and future prescription? An historical and scientific review. Pain 76:3\u20138","journal-title":"Pain"},{"key":"1888_CR81","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0165-5728(00)00307-6","volume":"109","author":"Sacerdote","year":"2000","unstructured":"Sacerdote P, Massi P, Panerai AE et al. (2000) In vivo and in vitro treatment with the synthetic cannabinoid CP55, 940 decreases the in vitro migration of macrophages in the rat: involvement of both CB1 and CB2 receptors. J Neuroimmunol 109:155\u2013163","journal-title":"J Neuroimmunol"},{"key":"1888_CR82","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1055\/s-2001-16510","volume":"69","author":"Schlimme","year":"2001","unstructured":"Schlimme J, Rada D, Schneider U (2001) [Cannabis consumption and its psychosocial effects in a comparison of different cultures]. Fortschr Neurol Psychiatr 69:367\u2013373","journal-title":"Fortschr Neurol Psychiatr"},{"key":"1888_CR83","unstructured":"Schnelle M, Grotenhermen F, Reif M et al. (1999) Results of a standardized survey on the medical use of cannabis products in the German-speaking area. Forsch Komplementarmed 6 [Suppl\u00a03]:28\u201336"},{"key":"1888_CR84","first-page":"CD001332","volume":"4","author":"Shakespeare","year":"2004","unstructured":"Shakespeare D, Boggild M, Young C (2004) Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 4:CD001332","journal-title":"Cochrane Database Syst Rev"},{"key":"1888_CR85","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1523\/JNEUROSCI.16-14-04322.1996","volume":"16","author":"Shen","year":"1996","unstructured":"Shen M, Piser TM, Seybold VS et al. (1996) Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J Neurosci 16:4322\u20134334","journal-title":"J Neurosci"},{"key":"1888_CR86","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","volume":"57","author":"Sieradzan","year":"2001","unstructured":"Sieradzan KA, Fox SH, Hill M et al. (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease: a pilot study. Neurology 57:2108\u20132111","journal-title":"Neurology"},{"key":"1888_CR87","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1152\/jn.1999.82.1.472","volume":"82","author":"Strangman","year":"1999","unstructured":"Strangman N, Walker J (1999) Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J Neurophysiol 82:472\u2013477","journal-title":"J Neurophysiol"},{"key":"1888_CR88","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1074\/jbc.275.1.605","volume":"275","author":"Sugiura","year":"2000","unstructured":"Sugiura T, Kondo S, Kishimoto S et al. (2000) Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 275:605\u2013612","journal-title":"J Biol Chem"},{"key":"1888_CR89","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0192-0561(92)90037-L","volume":"14","author":"Tang","year":"1992","unstructured":"Tang JL, Lancz G, Specter S et al. (1992) Marijuana and immunity: tetrahydrocannabinol-mediated inhibition of growth and phagocytic activity of the murine macrophage cell line, P388D1. Int J Immunopharmacol 14:253\u2013262","journal-title":"Int J Immunopharmacol"},{"key":"1888_CR90","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1300\/J251v07n01_04","volume":"7","author":"Ungerleider","year":"1987","unstructured":"Ungerleider JT, Andyrsiak T, Fairbanks L et al. (1987) Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 7:39\u201350","journal-title":"Adv Alcohol Subst Abuse"},{"key":"1888_CR91","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1385\/MN:26:2-3:317","volume":"26","author":"Van","year":"2002","unstructured":"Van Der Stelt M, Veldhuis WB, Maccarrone M et al. (2002) Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 26:317\u2013346","journal-title":"Mol Neurobiol"},{"key":"1888_CR92","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1191\/1352458504ms1048oa","volume":"10","author":"Vaney","year":"2004","unstructured":"Vaney C, Heinzel-Gutenbrunner M, Jobin P et al. (2004) Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 10:417\u2013424","journal-title":"Mult Scler"},{"key":"1888_CR93","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/376590a0","volume":"376","author":"Venance","year":"1995","unstructured":"Venance L, Piomelli D, Glowinski J et al. (1995) Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature 376:590\u2013594","journal-title":"Nature"},{"key":"1888_CR94","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D","volume":"12","author":"Volicer","year":"1997","unstructured":"Volicer L, Stelly M, Morris J et al. (1997) Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer\u2019s disease. Int J Geriatr Psychiatry 12:913\u2013919","journal-title":"Int J Geriatr Psychiatry"},{"key":"1888_CR95","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1191\/1352458504ms1082oa","volume":"10","author":"Wade","year":"2004","unstructured":"Wade D, Makela P, Robson P et al. (2004) Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 10:434\u2013441","journal-title":"Mult Scler"},{"key":"1888_CR96","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0024-3205(99)00289-1","volume":"65","author":"Walker","year":"1999","unstructured":"Walker J, Hohmann A, Martin W et al. (1999) The neurobiology of cannabinoid analgesia. Life Sci 65:665\u2013673","journal-title":"Life Sci"},{"key":"1888_CR97","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0006-8993(02)04274-9","volume":"967","author":"Werner","year":"2003","unstructured":"Werner N, Koch J (2003) Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats. Brain Res 967:290\u2013292","journal-title":"Brain Res"},{"key":"1888_CR98","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1164\/rccm.200306-775OC","volume":"170","author":"Yoshihara","year":"2004","unstructured":"Yoshihara S, Morimoto H, Yamada Y et al. (2004) Cannabinoid Receptor Agonists Inhibit Sensory Nerve Activation in Guinea Pig Airways. Am J Respir Crit Care Med 170:941\u2013946","journal-title":"Am J Respir Crit Care Med"},{"key":"1888_CR99","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","volume":"362","author":"Zajicek","year":"2003","unstructured":"Zajicek J, Fox P, Sanders H et al. (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362:1517\u20131526","journal-title":"Lancet"},{"key":"1888_CR100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4049\/jimmunol.165.1.373","volume":"165","author":"Zhu","year":"2000","unstructured":"Zhu LX, Sharma S, Stolina M et al. (2000) Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 165:373\u2013380","journal-title":"J Immunol"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-005-1888-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-005-1888-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-005-1888-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T01:00:46Z","timestamp":1558573246000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-005-1888-7"}},"subtitle":["Therapeutische Implikationen der Cannabinoide bei neurologisch-psychiatrischen Erkrankungen"],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":100,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["1888"],"URL":"https:\/\/doi.org\/10.1007\/s00115-005-1888-7","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}